This activity has expired. CME/CE credit is no longer available and the following content may not be available or may not be up-to-date. For a list of current activities that offer CME/CE credit, click here.

Printer-Friendly Email Page
Start the program at
the bottom of this page

Clinical Insights in Geriatrics: Setting the Stage: Stage-Specific Treatment Options for Patients With Moderate to Severe Alzheimer’s Disease
Release Date: December-16-11
Credit Expiration Date: September-16-13
Developer/Facilitator

.
Medium
Senior care providers including primary care physicians, long-term care physicians, nurses, consultant pharmacists, and others interested in the care of older patients with Alzheimer's disease.
Credit Hours
Family Physicians: 0.5 Prescribed credit
Nurses: 0.5 Contact Hours
Pharmacists: 0.5 Contact Hour (0.05 CEU)
Medium
i-Newsletter
Program Description
As the US population ages, dementia syndromes such as Alzheimer’s disease (AD) are growing more prevalent. Roughly 60% to 80% of elderly patients with chronic dementia have AD, a progressive condition that leads to memory loss, personality changes, cognitive dysfunction, and functional impairment. The Practice Guidelines for the Treatment of Patients With Alzheimer’s Disease and Other Dementias, 2nd Edition (2007) and other related guidelines stress the importance of individualized and multimodal treatment plans. Recognizing symptomatology of AD at its various stages can help providers select appropriate therapies.

Continuing education is required to help primary care providers and other senior care clinicians ensure that patients are being evaluated and treated properly. Patients with dementia need to be stratified based on the severity of their disease and treated accordingly, but many providers do not know how long to treat AD since there is no established standard on the duration of treatment.

Learning Objectives
Upon completion of this educational activity, the participant should be able to:
1.
Describe the evidence base for the stage-specific management of patients with AD.
2.
Tailor pharmacotherapy based on disease stage for individuals with moderate to severe AD.
faculty
David S. Geldmacher, MD, FACP
Charles and Patsy Collat Professor of Neurology
Director, Division of Memory Disorders and Behavioral Neurology
University of Alabama – Birmingham
Birmingham, AL

Lori A. Daiello, PharmD, BCPP
Assistant Professor of Neurology (Research)
Warren Alpert Medical School
Brown University
Cranston, RI

Elizabeth M. Galik, PhD, CRNP
Assistant Professor
University of Maryland School of Nursing
Baltimore, MD

Mary Campagnolo, MD, MBA, FAAFP, DABFM, CAQ-Geriatrics
Family Physician
Virtua-Lumberton Family Physicians
Lumberton, NJ



faculty
It is the policy of the AAFP, ASCP, and NADONA to ensure balance, independence, objectivity and scientific rigor in all of its educational activities including those which are sponsored and cosponsored. All faculty are expected to disclose any significant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation. The intent of this disclosure is not to prevent a presenter with significant financial interest or other relationship from making the presentation, but rather to provide the audience with information with which they can make their own judgments. It remains for the audience to determine whether the speaker's interests or relationships may influence the presentation with regard to exposition or conclusion. Faculty are also expected to openly disclose any off-label, experimental, or investigational use of drugs or devices in their presentations.

Dr. Geldmacher discloses the following: Consultant: Bayer, Eisai, Glaxo, Janssen; Grant/Research Support: Baxter, BMS, Janssen, Novartis, Pfizer.
Dr. Diaello discloses the following: Consultant: Eli Lilly.
Dr. Galnik discloses the following: Consultant: Novartis.
Dr. Campangola has no relevant financial conflicts to disclose.

ASCP:
Ms. Dechevalier has no relevant financial conflicts to disclose.
Dr. Gerber has no relevant financial conflicts to disclose.

NJAFP:
Ms. Barrett has no relevant financial conflicts to disclose.

NADONA:
Ms. Dornberger has no relevant financial conflicts to disclose.

MCM:
Dr. Thier has no relevant financial conflicts to disclose.
Dr. Paczolt has no relevant financial conflicts to disclose.
Dr. Lee has no relevant financial conflicts to disclose.

This educational activity may contain discussion of published and/or investigational uses of pharmaceutical agents. Some uses of these agents may not have been approved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Credit Statements
This Enduring Material activity, Clinical Insights in Geriatrics: Setting the Stage: Stage-Specific Treatment Options for Patients With Moderate to Severe Alzheimer’s Disease, has been reviewed and is acceptable for up to 0.50 Prescribed credits by the American Academy of Family Physicians. AAFP accreditation begins December 15, 2011. Term of approval is for one year from this date. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The American Society of Consultant Pharmacists (ASCP) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This knowledge-based activity, ACPE Universal Activity #0203-9999-11-163-H01-P, has been assigned 0.5 Contact Hour (0.05 CEU).
NADONA/LTC is an approved provider of continuing nursing education by Georgia Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation #1088. This activity provides 0.5 contact hour by NADONA/LTC.


Participants must view the activity in its entirety, successfully complete the post-test, and submit an evaluation to receive continuing pharmacy education credit. Credit will be awarded for a score of 80% or better, and a statement may be printed immediately after passing the post-test.

There is no fee to participate in this educational activity.
Commercial Support Statements
This activity is supported by an educational grant from Pfizer Inc.
Instructions
Minimum System Requirements: • Pentium III, 600 MHz or Equivalent Processor • 512 MB of RAM • Windows XP, Vista, or 7 • Mac OS X • 800x600 Monitor Resolution • 16-bit Color • 16 bit Sound Card with Speakers
1.
Please turn off all pop-up blockers to assure access to the educational activity.
2.
Click on the "Start program" icon at the bottom of this page. If you are not already registered as a user of this website, this will bring you to the login/registration page where you will be able to register as a new CMEcorner.com member or check existing registration information. When ready, click on the "Continue to Program" icon at the bottom of the screen.
3.
The next screen will permit you to check for or download the Flash player required to run this program and to begin the program presentation. The activity will take approximately 30 minutes to complete.
4.
After the activity has finished, click on the "Post-test" button.
5.
Instructions for completing and submitting the post-test and evaluation are provided on the post-test screen.
Certificate Fee

$0.00

Disclaimer
© 2011, Medical Communications Media, Inc. All rights reserved. None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, ASCP, NJAFP, NADONA, or Pfizer Inc. Any medications, diagnostic procedures, or treatments discussed by the faculty should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.
Printer-Friendly Email Page Start Program as a Guest
Start Program
By clicking START PROGRAM I acknowledge that I have read the CME/CE information above.